California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

California State Teachers Retirement System lowered its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 10.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 114,591 shares of the biotechnology company’s stock after selling 13,824 shares during the period. California State Teachers Retirement System owned approximately 0.08% of Aurinia Pharmaceuticals worth $1,029,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Tang Capital Management LLC increased its position in shares of Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock valued at $75,697,000 after acquiring an additional 1,200,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock valued at $15,535,000 after acquiring an additional 112,113 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Aurinia Pharmaceuticals by 10.2% during the fourth quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company’s stock valued at $13,401,000 after acquiring an additional 138,054 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $9,662,000. Finally, Northern Trust Corp increased its position in shares of Aurinia Pharmaceuticals by 5.9% during the fourth quarter. Northern Trust Corp now owns 1,054,365 shares of the biotechnology company’s stock valued at $9,468,000 after acquiring an additional 58,676 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 0.1%

NASDAQ:AUPH opened at $8.15 on Wednesday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12 month low of $5.15 and a 12 month high of $10.67. The company has a market cap of $1.10 billion, a PE ratio of -54.33 and a beta of 1.15. The company has a 50 day simple moving average of $7.95 and a two-hundred day simple moving average of $8.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.08. The business had revenue of $62.47 million for the quarter, compared to analysts’ expectations of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Research analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.